Solange Peters
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
Furrer K, Weder W, Eboulet E, Betticher D, Pless M, Stupp R, Krueger T, Perentes J, Schmid R, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel R, Rothschild S, Hayoz S, Opitz I. Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. J Thorac Cardiovasc Surg 2022; 164:1587-1602.e5.
Apr 18, 2022Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
Apr 18, 2022J Thorac Cardiovasc Surg 2022; 164:1587-1602.e5
Furrer Katarzyna, Weder Walter, Eboulet Eric Innocents, Betticher Daniel, Pless Miklos, Stupp Roger, Krueger Thorsten, Perentes Jean Yannis, Schmid Ralph A, Lardinois Didier, Furrer Markus, Früh Martin, Peters Solange, Curioni-Fontecedro Alessandra, Stahel Rolf A, Rothschild Sacha I, Hayoz Stefanie, Opitz Isabelle
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
Rothschild S, Cathomas R, Ochsenbein A, Janthur W, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Mark M, Peters S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, Früh M, Jörger M, Lardinois D, Gelpke H, Mauti L, Britschgi C, Weder W, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol 2021; 39:2872-2880.
Jul 12, 2021SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
Jul 12, 2021J Clin Oncol 2021; 39:2872-2880
Rothschild Sacha I, Cathomas Richard, Ochsenbein Adrian F, Janthur Wolf-Dieter, Waibel Christine, Mach Nicolas, Froesch Patrizia, Buess Martin, Bohanes Pierre, Godar Gilles, Rusterholz Corinne, Gonzalez Michel, Pless Miklos, Mark Michael, Peters Solange, Zippelius Alfred, Eboulet Eric I, Savic Prince Spasenija, Betticher Daniel, Bettini Adrienne, Früh Martin, Jörger Markus, Lardinois Didier, Gelpke Hans, Mauti Laetitia A, Britschgi Christian, Weder Walter, Swiss Group for Clinical Cancer Research (SAKK)
Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
Schmid S, Früh M, Peters S. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?. Lancet Oncol 2020; 21:320-322.
Feb 3, 2020Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
Feb 3, 2020Lancet Oncol 2020; 21:320-322
Schmid Sabine, Früh Martin, Peters Solange
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
Molina-Vila M, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Palmero R, Massutí B, Stahel R, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Rosell R. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. J Thorac Oncol 2019; 15:416-425.
Dec 5, 2019Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
Dec 5, 2019J Thorac Oncol 2019; 15:416-425
Molina-Vila Miguel-Angel, Ponce Aix Santiago, Carcereny Enric, Früh Martin, Pless Miklos, Popat Sanjay, Cuffe Sinead, Bidoli Paolo, Kammler Roswitha, Roschitzki-Voser Heidi, Tsourti Zoi, Karachaliou Niki, Palmero Ramon, Massutí Bartomeu, Stahel Rolf A, Dafni Urania, Jordana-Ariza Núria, Balada-Bel Ariadna, Garzón-Ibáñez Mónica, García-Peláez Beatriz, Mayo-de-Las-Casas Clara, Felip Enriqueta, Curioni Fontecedro Alessandra, Gautschi Oliver, Peters Solange, Rosell Rafael
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Früh M, Guckenberger M, Rothschild S, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Weder W, Stahel R, Matzinger O, Betticher D, Stupp R, Xyrafas A, Peters S, Ris H, Mirimanoff R, Ochsenbein A, Schmid R, Pless M. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol 2018
Sep 26, 2018Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Sep 26, 2018J Thorac Oncol 2018
Früh Martin, Guckenberger Matthias, Rothschild Sacha I, Lardinois Didier, Mach Nicholas, Mark Michael, Gautschi Oliver, Thierstein Sandra, Biaggi Rudolf Christine, Weder Walter, Stahel Rolf A, Matzinger Oscar, Betticher Daniel C, Stupp Roger, Xyrafas Alexandros, Peters Solange, Ris Hans Beat, Mirimanoff Rene Olivier, Ochsenbein Adrian F, Schmid Ralph, Pless Miklos
Genomic Features of Response to Combination Immunotherapy in Lung Cancer
Früh M, Peters S. Genomic Features of Response to Combination Immunotherapy in Lung Cancer. Cancer Cell 2018; 33:791-793.
May 14, 2018Genomic Features of Response to Combination Immunotherapy in Lung Cancer
May 14, 2018Cancer Cell 2018; 33:791-793
Früh Martin, Peters Solange
EML4-ALK Variant Affects ALK Resistance Mutations
Früh M, Peters S. EML4-ALK Variant Affects ALK Resistance Mutations. J Clin Oncol 2018; 36:1257-1259.
Mar 1, 2018EML4-ALK Variant Affects ALK Resistance Mutations
Mar 1, 2018J Clin Oncol 2018; 36:1257-1259
Früh Martin, Peters Solange
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Peters S, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd F, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Früh M, Ho C, Gettinger S, Johnson M, Jänne P, Garassino M, Christoph D, Toh C, Rizvi N, Chaft J, Carcereny Costa E, Patel J, Chow L, Koczywas M, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 2017; 35:2781-2789.
Jun 13, 2017Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Jun 13, 2017J Clin Oncol 2017; 35:2781-2789
Peters Solange, van den Heuvel Michel, Rothenstein Jeffrey, Reck Martin, Paz-Ares Luis, Shepherd Frances A, Kurata Takayasu, Li Zhengrong, Qiu Jiaheng, Kowanetz Marcin, Mocci Simonetta, Shankar Geetha, Sandler Alan, Früh Martin, Ho Cheryl, Gettinger Scott, Johnson Melissa L, Jänne Pasi A, Garassino Marina C, Christoph Daniel, Toh Chee Keong, Rizvi Naiyer A, Chaft Jamie E, Carcereny Costa Enric, Patel Jyoti D, Chow Laura Q M, Koczywas Marianna, Felip Enriqueta
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rosell R, Shah R, Porta R, Majem M, Gómez-Codina J, Camps C, Thomas M, Rauch D, Barlesi F, Hanrahan E, Kammler R, Stahel R, Molina-Vila M, Shames D, Tam R, Karachaliou N, Kassapian M, Rabaglio M, Ruepp B, Coate L, Puente J, Aix S, Palmero R, Massutí B, Peters S, Gautschi O, Curioni-Fontecedro A, Felip E, Dafni U, Carcereny E, Früh M, Reguart N, Froesch P, Favaretto A, Bidoli P, Cuffe S, Kotsakis A, Popat S, Pless M, BELIEF collaborative group. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 2017; 5:435-444.
Apr 10, 2017Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Apr 10, 2017Lancet Respir Med 2017; 5:435-444
Rosell Rafael, Shah Riyaz, Porta Rut, Majem Margarita, Gómez-Codina Jose, Camps Carlos, Thomas Michael, Rauch Daniel, Barlesi Fabrice, Hanrahan Emer, Kammler Roswitha, Stahel Rolf A, Molina-Vila Miguel A, Shames David S, Tam Rachel, Karachaliou Niki, Kassapian Marie, Rabaglio Manuela, Ruepp Barbara, Coate Linda, Puente Javier, Aix Santiago Ponce, Palmero Ramon, Massutí Bartomeu, Peters Solange, Gautschi Oliver, Curioni-Fontecedro Alessandra, Felip Enriqueta, Dafni Urania, Carcereny Enric, Früh Martin, Reguart Noemí, Froesch Patrizia, Favaretto Adolfo, Bidoli Paolo, Cuffe Sinead, Kotsakis Athanasios, Popat Sanjay, Pless Miklos, BELIEF collaborative group
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Gautschi O, Ochsenbein A, Mach N, Biaggi C, Schneider M, Zander T, Froesch P, Peters S, Pless M, Rauch D, Cathomas R, Stahel R, Früh M, Betticher D, Zippelius A, Matter-Walstra K, Li Q, Rothschild S. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer 2016
Nov 23, 2016Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Nov 23, 2016Clin Lung Cancer 2016
Gautschi Oliver, Ochsenbein Adrian F, Mach Nicolas, Biaggi Christine, Schneider Martina, Zander Thilo, Froesch Patrizia, Peters Solange, Pless Miklos, Rauch Daniel, Cathomas Richard, Stahel Rolf A, Früh Martin, Betticher Daniel C, Zippelius Alfred, Matter-Walstra Klazien, Li Qiyu, Rothschild Sacha I
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
Stahel R, Caspar C, Eckhardt K, Schmid R, Aebersold D, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik L, Mordasini C, Zippelius A, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 2015; 16:1651-8.
Nov 2, 2015Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
Nov 2, 2015Lancet Oncol 2015; 16:1651-8
Stahel Rolf A, Caspar Clemens B, Eckhardt Katrin, Schmid Ralph A, Aebersold Daniel M, Gautschi Oliver, Nagel Wolfgang, Töpfer Michael, Krayenbuehl Jerome, Ribi Karin, Ciernik Llja F, Mordasini Carlo, Zippelius Alfred, Riesterer Oliver, Xyrafas Alexandros, Opitz Isabelle, Beyeler Michael, Ochsenbein Adrian, Früh Martin, Cathomas Richard, Nackaerts Kristiaan, Peters Solange, Mamot Christoph, Weder Walter
[Is prescription of a therapy costing 150,000 CHF reasonable?]
Peters S, von Moos R, Thürlimann B. [Is prescription of a therapy costing 150,000 CHF reasonable?]. Rev Med Suisse 2015; 11:1967-72.
Oct 21, 2015[Is prescription of a therapy costing 150,000 CHF reasonable?]
Oct 21, 2015Rev Med Suisse 2015; 11:1967-72
Peters Solange, von Moos Roger, Thürlimann Beat
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Gautschi O, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Huret B, Curioni-Fontecedro A, Milia J, Cabarrou B, Bluthgen M, Besse B, Smit E, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol 2015; 10:1451-7.
Oct 1, 2015Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Oct 1, 2015J Thorac Oncol 2015; 10:1451-7
Gautschi Oliver, Kerjouan Mallorie, Michels Sebastian, Pall Georg, Rothschild Sacha, Schmid-Bindert Gerald, Scheffler Matthias, Veillon Rémi, Wannesson Luciano, Diebold Joachim, Zalcman Gérard, Filleron Thomas, Huret Benjamin, Curioni-Fontecedro Alessandra, Milia Julie, Cabarrou Bastien, Bluthgen Marie-Virginia, Besse Benjamin, Smit Egbert F, Wolf Juergen, Peters Solange, Früh Martin, Koeberle Dieter, Oulkhouir Youssouf, Schuler Martin, Mazières Julien
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Pless M, Bijelovic M, Ochsenbein A, Meier U, Mamot C, Rauch D, Gautschi O, Betticher D, Mirimanoff R, Peters S, Roth A, Zippelius A, Stupp R, Ris H, Stahel R, Weder W, Thierstein S, Gerard M, Xyrafas A, Früh M, Cathomas R. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 2015; 386:1049-56.
Aug 11, 2015Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Aug 11, 2015Lancet 2015; 386:1049-56
Pless Miklos, Bijelovic Milorad, Ochsenbein Adrian, Meier Urs R, Mamot Christoph, Rauch Daniel, Gautschi Oliver, Betticher Daniel C, Mirimanoff René-Olivier, Peters Solange, Roth Arnaud, Zippelius Alfred, Stupp Roger, Ris Hans-Beat, Stahel Rolf A, Weder Walter, Thierstein Sandra, Gerard Marie-Aline, Xyrafas Alexandros, Früh Martin, Cathomas Richard
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer 2015; 16:358-65.
Mar 5, 2015Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Mar 5, 2015Clin Lung Cancer 2015; 16:358-65
Gautschi Oliver, Savic Spasenija, Jaggi Rolf, Leibundgut Elisabeth Oppliger, Largiadèr Carlo, Brutsche Martin, Pilop Christiane, Stalder Lukas, Pless Miklos, Ochsenbein Adrian F, Bubendorf Lukas, Feilchenfeldt Jonas, Rauch Daniel, Mach Nicholas, Rothschild Sacha I, Li Qiyu, Stahel Rolf A, Zippelius Alfred, Cathomas Richard, Früh Martin, Betticher Daniel C, Peters Solange, Swiss Group for Clinical Cancer Research
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Gautschi O, Stahel R, Carbone D, Na K, Hsu Schmitz S, Bubendorf L, Baty F, Brutsche M, Pless M, Zappa F, Roder J, Grigorieva J, Roder H, Peters S, Crowe S, Dingemans A, Smit E. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer 2012; 79:59-64.
Nov 1, 2012VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Nov 1, 2012Lung Cancer 2012; 79:59-64
Gautschi Oliver, Stahel Rolf, Carbone David, Na Kyung-Jae, Hsu Schmitz Shu-Fang, Bubendorf Lukas, Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Roder Joanna, Grigorieva Julia, Roder Heinrich, Peters Solange, Crowe Susanne, Dingemans Anne-Marie, Smit Egbert
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
Pesce G, Bernhard J, Kotrubczik N, D'Addario G, Pilop C, Weber D, Bodis S, Pless M, Mayer M, Cathomas R, Peters S, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar C, Fischer N, Anchisi S, Stupp R. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer 2011; 48:377-84.
Nov 15, 2011Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
Nov 15, 2011Eur J Cancer 2011; 48:377-84
Pesce Gianfranco A, Bernhard Jürg, Kotrubczik Nina M, D'Addario Giannicola, Pilop Christiane, Weber Damien C, Bodis Stephan, Pless Miklos, Mayer Michael, Cathomas Richard, Peters Solange, Klingbiel Dirk, Ribi Karin, Zouhair Abderahim, von Moos Roger, Schlaeppi Marc, Caspar Clemens B, Fischer Natalie, Anchisi Sandro, Stupp Roger